Often, what happens in science is you got a problem and you solve it, and then there’s not much else to do and you have to move on. But the ribosome turned out to be a rather rich gold mine. Perhaps I’m a little intellectually lazy and feel like, “Why should I bother thinking about something else?” Maybe at some point, I should have thought, “I should do something different.”

Ironically, though, this is also the purchase in which I made my biggest mistake - of a kind, however, never recognized on financial statements. We paid $600 million in 1989 for Gillette preferred shares that were convertible into 48 million (split-adjusted) common shares. Taking an alternative route with the $600 million, I probably could have purchased 60 million shares of common from the company. The market on the common was then about $10.50, and given that this would have been a huge private placement carrying important restrictions, I probably could have bought the stock at a discount of at least 5%. I can't be sure about this, but it's likely that Gillette's management would have been just as happy to have Berkshire opt for common. But I was far too clever to do that.

I probably want to be liked too much. This is one difference between me and Steve Levitt . Steve Levitt is also much smarter than me and much more successful than me. And that doesn’t bother me at all, but he said he also doesn’t care what anyone thinks about him, or doesn’t seem to care what anyone thinks about him. I actually do care what people think about me. I’d quite like people to think I’m a nice guy, so I’m probably self-censoring at times. Say, maybe I won’t say that because people wouldn’t like that. And that’s probably a fault in a newspaper columnist — you probably shouldn’t care what people think about you, but that’s the way it is.

I’m prone to overexplaining things –- when my own understanding of them is shaky. The better I know something, the shorter my prose.